Effect of intrinsic sphincter deficiency on treatment success following urethral bulking with polyacrylamide hydrogel Authors: Bertie Geng, Layla Joudeh, Ayanna Garland, Elizabeth J. Geller Published: 2026 ABSTRACT PurposeIntrinsic sphincter deficiency (ISD) is associated with lower stress urinary incontinence (SUI) treatment success. Polyacrylamide hydrogel (PH) is a widely used urethral bulking material in treating SUI. Our goal is to compare treatment outcomes in women with and without ISD who underwent urethral bulking with PH for SUI.Materials and MethodsWe conducted a retrospective cohort analysis of women who underwent urethral bulking with PH from October 2022 to November 2024. Exclusions included no SUI on preoperative urodynamics, prior surgical SUI treatment, or no follow-up visit. ISD was defined as cough or Valsalva leak point pressure ≤60 cm H2O or maximal urethral closure pressure ≤20 cm H2O on preoperative urodynamics. Treatment success was defined as no SUI or improved SUI at initial follow-up.ResultsOf the 171 participants included, 21 (12.3%) met criteria for ISD. Those with ISD were older and received a greater amount of PH compared to those without ISD (1.79 mL vs. 1.65 mL, p=0.05). There were no differences in self-reported race/ethnicity, body mass index, parity, or rates of concomitant prolapse repair. There were no differences in uroflow or micturition pattern or bladder sensation on preoperative urodynamics. Treatment success was high in both (95.2% with ISD vs. 89.9% without ISD, p=0.70). Rates of SUI retreatment were low in both and did not differ.ConclusionsWhile there were some differences between those with and without ISD, both had high treatment success rates. Using PH bulking injection to treat SUI in those with ISD is reasonable. INTRODUCTION Stress urinary incontinence (SUI), which is the involuntary loss of urine with coughing, sneezing, or physical exertion, is estimated to impact 30%–50% of adult women in the United States [12]. Two main mechanisms are thought to contribute to the pathophysiology of SUI: urethral hypermobility and intrinsic sphincter deficiency (ISD) [3]. ISD results from the loss of urethral sphincter muscle tone and is diagnosed on multichannel urodynamic study (UDS) as either a cough or Valsalva leak point pressure (LPP) of ≤60 cm H2O or maximal urethral closure pressure (MUCP) of ≤20 cm H2O [3]. Abdominal LPP is defined as urinary leakage due to an increase in intravesical pressure generated by increased intra-abdominal pressure rather than a detrusor contraction. MUCP is defined as the difference between urethral and intravesical pressure and is thought to reflect the ability of the urethra to help maintain continence [4]. Urethral bulking is the least invasive surgical treatment option for SUI, but can have variable treatment outcomes, with reported 1-year treatment success rates ranging from 10%–80% [5678]. While there have been a variety of different available urethral bulking agents, Bulkamid®, a homogenous polyacrylamide hydrogel (PH), is a widely used agent that has shown a 67.1% cure or improvement rate on 7-year follow-up [9]. These studies do not differentiate ISD from non-ISD outcomes, and ISD is often associated with more severe SUI symptoms and lower treatment success rates [110]. Thus, our aim was to compare treatment outcomes in those with and without ISD who underwent urethral bulking injection with PH for SUI. MATERIALS AND METHODS This was a retrospective cohort analysis of individuals who underwent urethral bulking injection with PH at the University of North Carolina, a large academic center, from October 2022 to November 2024. Participants were excluded if they did not demonstrate SUI on preoperative multichannel UDS, had any prior surgical treatment for SUI, or did not present for a post-procedure follow-up visit. ISD was defined as described above. Treatment selection for urethral bulking was based on patient preference after standardized counseling. Participants were included if they underwent isolated urethral bulking or urethral bulking with concomitant prolapse repair, including hysterectomy with apical suspension, anterior or posterior repair, sacrocolpopexy, or colpoclesis. Treatment success was defined as patient reported lack of SUI symptoms or improved SUI symptoms as documented in the first post-procedure follow-up visit. All bulking injections were performed in a standard fashion per manufacturer recommendations [11] with transurethral injection via urethroscopy by fellowship trained urogynecologists with patients in the lithotomy position. All PH injections were performed into the submucosal tissue 2 cm distal to the bladder neck. Injections were performed with fluid inflow on to dilate the urethra at 7, 11, 1, and 5 o’clock and PH injected until the urethra demonstrated visual bleb formation at each site, ultimately resulting in circumferential coaptation [12]. The volume of PH injected was calculated based on the amount remaining in the syringes after the injection was complete (with a starting maximum volume of 2 mL for each patient). All patients received preprocedure antibiotics. Patients who underwent the procedure in the operating room (OR) received a single dose of intravenous antibiotics and those who underwent bulking in the office setting received oral antibiotic prophylaxis for 3 days, starting the day prior to the procedure. Baseline demographics, UDS results, and treatment outcomes were extracted from the medical record. In our practice, patients planning prolapse surgery typically undergo UDS prior to surgery to assess for occult SUI. Occult SUI is defined as SUI only seen on UDS with reduction of prolapse in patients without baseline SUI symptoms. During the 6-week post procedure visit, all patients (including those with occult SUI) were asked if they experienced any SUI symptoms, which represents question 3 on the urinary distress inventory (UDI)-6 subscale of the Pelvic Floor Distress Inventory (PFDI) 20 questionnaire [13]: “Do you usually experience urine leakage related to coughing, sneezing, or laughing?” If any patients reported having any SUI symptoms post procedure, they were asked if their symptoms were improved, worsened, or unchanged from pre procedure. Patients did not complete validated incontinence questionnaires and objective SUI testing was not performed. Participants who underwent bulking in the OR underwent formal void trial in the recovery room. Participant voided volume and post-void residual (PVR) recorded on bladder scan are recorded. A participant was considered to have passed the voiding trial if they had a PVR <150 mL. Those who did not pass voiding trial following were discharged with a 14-French or smaller Foley catheter for 1–3 days. Participants subsequently removed the catheter at home or in the office. Statistical analysis included Student’s t-test, Fisher’s exact test, and chi-square test using IBM SPSS version 29.0.1.0 (IBM Corp.). This study received Institutional Review Board of the University of North Carolina at Chapel Hill approval (approval number: 24-2630). The written informed consent was waived due to the study’s retrospective design. RESULTS A total of 171 individuals were included in the study, of which 21 (12.3%) met criteria for ISD. The mean age at initial bulking was older for those with ISD compared to those without ISD and those with ISD were more likely to be menopausal (Table 1). Otherwise, there were no differences in self-reported race/ethnicity, body mass index, parity, diabetes, smoking status, neurologic disease, history of prior pelvic radiation, prior hysterectomy or vaginal surgery, preoperative symptomatic SUI, overactive bladder symptoms or treatment, or preoperative prolapse severity. Those with ISD received a higher amount of PH bulking material compared to those without ISD (1.79 mL vs. 1.65 mL, p=0.05). The location of the bulking procedure (OR vs. office) and the rate of concomitant surgical procedures (including hysterectomy, sacrocolpopexy, and colpoclesis) did not differ between groups (all p>0.05). We also assessed urodynamics characteristics between those with and without ISD. As expected, we found those with ISD had lower cough and Valsalva LPP’s and lower MUCP than those without ISD on preoperative UDS (Table 2). There were no differences in uroflow pattern, bladder sensation, presence of detrusor overactivity, micturition pattern or postvoid residual between groups. For our primary outcomes, we compared treatment success rates between those with and without ISD. Treatment success was defined as a composite of no SUI or improved SUI at first postoperative visit. We found that treatment success was high in both groups and did not differ between groups (95.2% with ISD vs. 89.9% without ISD, p=0.70) (Table 3). Of those who reported having any SUI at first follow-up visit, the majority of both groups (88.9% of those with ISD and 77.6% of those without ISD) reported an improvement in SUI symptoms compared to preoperatively (p=0.68). None reported worse symptoms post-procedure. There were no differences in the rates of urinary retention between groups. For our secondary outcome, rates of SUI retreatment after initial bulking procedure (with either repeat bulking injection or mesh sling) were low in both groups, with no differences between groups. The overall SUI retreatment rate following bulking was 17.0% (29/171), with 17 participants undergoing repeat bulking, 5 undergoing mesh sling, and 2 undergoing both repeat bulking and mesh sling. An additional 5 participants opted for nonsurgical SUI retreatment. On sub-group analysis of those with symptomatic SUI (excluding those with occult SUI) we found that there continued to be no difference in treatment success rate between groups (93.8% with ISD vs. 88.0% without ISD, p=0.70). There also continued to be no difference in the rates of participants who reported any SUI on initial follow-up (56.3% with ISD vs. 54.0% without ISD, p>0.99). Of those reporting having any SUI on initial follow-up, the majority of both groups continued to report improvement in SUI symptoms compared to preoperatively (88.9% with ISD vs. 77.6% without ISD, p=0.68). Additionally there continued to be no differences in those who reported having any SUI at last follow-up (50.0% with ISD vs. 53.5% without ISD, p>0.99) and no differences in rates of SUI retreatment (12.5% with ISD vs. 21.4% without ISD, p=0.53). When comparing those with symptomatic SUI to those with occult SUI (only seen on UDS but no active SUI symptoms), there were no differences in rates of ISD (11.3% in symptomatic SUI group vs. 17.2% in occult SUI group, p=0.36). There were no differences in treatment success between the two groups (88.7% vs. 100.0%, p=0.08); although the occult SUI group had 100% success rate. The symptomatic SUI group was more likely to report any SUI on initial postop visit (54.2% vs. 3.4%, p<0.001) and last office visit (52.9% vs. 3.4%, p<0.001). The symptomatic SUI group was more likely to undergo retreatment than the occult SUI group (20.4% vs. 0.0%, p=0.005). DISCUSSION We found that those with ISD had high treatment success rates at initial post-procedure visit following urethral bulking with PH that did not differ from those without ISD. Women with ISD also did not have higher retreatment rates than those without ISD. Surgical procedures that are targeted at correcting SUI, such as the Burch retropubic urethropexy, are known to have high failure rates in patients with ISD [10]. Additionally, multiple studies examining the effectiveness of midurethral sling have found lower success rates for patients with lower preoperative LPPs and MUCP [141516]. One study of 729 women reported 1-year cure rate of 43.8% for those with MUCP <20 (defined as ISD), compared to 76.5% for those with MUCP <40 but ≥20 and over 90% cure rate for those with MUCP ≥40 [15]. The majority of data on bulking outcomes in patients with ISD report on older bulking materials, with 1–2 year success rates following Macroplastique® (polydimethylsiloxane) injection ranging from 40%–80% [81718]. Martan et al. [19] reported on 52 patients who underwent PH bulking injection, 12 with ISD and 40 of whom had failed prior SUI treatment, and found that 15.7% were completely dry based on International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form questionnaire, while 45.1% were subjectively dry or improved. The authors also found 19.6% had negative cough stress tests [19]. They did not report separate outcomes for those with ISD. A strength of this study is that it was conducted in a large academic center with a relatively large number of participants over a multi-year time frame. Another advantage is that although it was retrospective, the data were collected in real time at the time of the post-procedure visit, which avoids recall bias. Another strength of the study is that many perioperative patient factors were assessed and we included participants who had both symptomatic and occult SUI and those who underwent concomitant prolapse repair surgery, thus increasing the generalizability of our study findings. Because our study included those with both symptomatic and occult SUI, we performed separate sub-group analysis excluding those with occult SUI. The findings of our sub-group analysis were similar to our general analysis, mainly that those with ISD continued to have high treatment success and low retreatment rates following urethral bulking injection with PH and that these rates did not differ compared to the group without ISD. A limitation of the study is the retrospective cohort study design; which can lead to potential confounders such as recall bias or selection bias. While the study is retrospective, the data collected were recorded in real time which would reduce the potential of recall bias. Selection bias is less common in a cohort study compared to a case-control study where one is identifying participants based on disease state rather than exposure. Another limitation is that our primary outcome is based on short-term (6 weeks post-procedure) patient-report of SUI rather than validated questionnaire or objective SUI measurement. However, the concept of patient reported bother is central to the purpose of outcomes-based research, rather than the objective cure rate of a treatment. Studies have found that while objective cure rates are often lower than patient-reported subjective cure rates, the patient reported satisfaction often matches the higherpatient reported symptom relief [2021]. Use of SUI responses from a validated questionnaire such as the Pelvic Floor Distress Inventory would be optimal, but it is not a part of our standard clinical practice to administer questionnaire and thus this information was not available at the time of chart review [2223]. However, patients were queried with similar verbiage to question 3 of the UDI-6 subscale of the PFDI-20 [13], which is “Do you usually experience urine leakage related to coughing, sneezing, or laughing?” While our follow-up period is short-term, our primary outcome is focused on comparing early symptomatic improvement between those with and without ISD. Furthermore, while there is variation between groups in the time from bulking to most recent office visit (with the ISD group having fewer days from bulking to most recent visit), time for initial routine follow-up was more similar (84.1 days vs. 61.3 days) as well as for our secondary outcome of SUI treatment (214.7 days vs. 188.0 days). Additionally, the number of individuals with ISD in our study is relatively small at 12%, so we may be underpowered to find a difference in cure rates. Our study found that both groups overall had a high cure rate and thus there is potential for type II error. However, our rate of ISD reflects the low rate found in the general population of individuals with SUI [2425]. Additionally, there was a high rate of concomitant prolapse repair in our study. While the rates of concomitant prolapse repair did not differ between those with and without ISD, this lack of difference may be due to lack of power for this outcome. CONCLUSIONS While there were some demographic and urodynamic differences between those with and without ISD, both groups had high treatment success rates. Using PH bulking injection to treat SUI in those with ISD is a reasonable treatment option.